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Abstract 
 
Background and Aims: To reduce hepatitis C virus (HCV) transmission among people who inject 
drugs (PWID), Scottish Government-funded national strategies, launched in 2008, promoted scaling-
up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some increases in 
HCV treatment. We test whether observed decreases in HCV incidence post-2008 can be attributed 
to this intervention scale-up. 
 
Design: A dynamic HCV transmission model amongst PWID incorporating intervention scale-up and 
observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence data for 
2008/09.    
 
Setting: Scotland, UK 
 
Participants: PWID 
  
Measurements: Model projections from 2008-2015 were compared with data to test whether they 
were consistent with observed decreases in HCV incidence amongst PWID while incorporating the 
observed intervention scale-up, and to determine the impact of scaling-up interventions on 
incidence.   
 
Findings: Without fitting to epidemiological data post-2008/09, the model incorporating observed 
intervention scale-up agreed with observed decreases in HCV incidence amongst PWID between 
2008-2015, suggesting HCV incidence decreased by 61.3% (95% credibility interval 45.1-75.3%) from 
14.2/100pyrs (9.0-20.7) to 5.5/100pyrs (2.9-9.2). On average, each model fit lay within 84% (10.1/12) 
of the confidence bounds for the 12 incidence data points which the model was compared against. 
We estimate that scale-up of interventions (OST+NSP+HCV treatment) and decreases in high-risk 
behaviour from 2008-2015 resulted in a 33.9% (23.8-44.6%) decrease in incidence, with the 
remainder (27.4% (17.6-37.0%)) explained by historical changes in OST+NSP coverage and risk pre-
2008. Projections suggest scaling-up of all interventions post-2008 averted 1,492 (657-2,646) 
infections over 7-years, with 1,016 (308-1,996), 404 (150-836) and 72 (27-137) due to scale-up of 
OST+NSP, decreases in high-risk behaviour, and HCV treatment, respectively.  
 
Conclusions: Most of the decline in hepatitis C virus (HCV) incidence in Scotland between 2008-2015 
appears to be attributable to intervention scale-up (opioid substitution therapy and needle and 
syringe provision) due to government strategies on HCV and drugs.   
 
 
Keywords: Hepatitis C, people who inject drugs, injecting drug users, opioid substitution therapy, 
needle and syringe programmes, Scotland 
  
Introduction 
Hepatitis C virus (HCV) is a blood-borne disease with high global burden(1), and a leading cause of 
death and morbidity(2,3). It is estimated that 90% of HCV infections in Scotland are acquired through 
injecting drug use(4), with people who inject drugs (PWID) harbouring a high burden of infection 
(54% sero-prevalence in 2008/09(5,6)).  
 
Evidence suggests that needle and syringe provision (NSP) and opioid substitution therapy (OST) can 
reduce an individual’s risk of HCV acquisition(7), but little evidence exists of their impact at the 
population-level(8-11). Modelling has estimated the impact of these interventions on HCV 
transmission at the population-level(12,13), as well as the impact of HCV treatment as 
prevention(14,15), however no analyses have validated their projections against epidemiological 
data.  
 
In Scotland, NSP and OST were introduced in the 1980s, increasing incrementally since then, with 
their scale-up credited to decreasing HCV prevalence amongst PWID in the 1990s(16,17). However, 
HCV prevalence has remained high since then and new presentations for HCV-related liver 
failure/cancer have been increasing(4,5). Therefore, in 2008, the Scottish government launched a 
national action plan for HCV, aiming to reduce HCV transmission amongst PWID alongside reducing 
HCV-related morbidity. The strategy was underpinned by additional investment above existing HCV 
funding (~100 million during 2008-15) and focussed on scaling-up harm reduction interventions 
(particularly providing needle/syringes and other injecting equipment) and HCV testing/treatment 
services(4,18). Contemporaneously, the Scottish Government published a new drug and alcohol 
strategy, setting out a programme to tackle Scotland’s drug problem and reduce waiting times for 
drug treatment; thus having the potential to impact the delivery of OST(19). Over the first 3 years of 
these strategies (2008/09 to 2011/12), the scale-up of high coverage needle and syringe provision 
(high coverage NSP – defined as exchanging at least one sterile needle/syringe per injection) 
increased by 40%(5), OST coverage increased by 30%(5), and annual numbers of HCV treatments 
doubled to 1,000(4), with almost half amongst current or temporarily ceased PWIDs (mostly on 
OST).  Concurrently, a halving in HCV incidence occurred(5). However, there was no control 
comparison for this nationwide programme; and so it is difficult to determine whether this decrease 
in HCV incidence occurred due to the intervention scale-up, or would have occurred anyway. Similar 
issues have been addressed in the HIV-field by using modelling to determine whether observed 
changes in disease transmission are consistent with the scale-up of specific interventions(11,20-24). 
 
We model the transmission of HCV among PWID in Scotland using data from national cross-sectional 
surveys carried out between 2008 and 2014. A dynamic, deterministic model is implemented to 
capture all intervention components and behavioural changes, enabling us to quantify how they may 
have affected transmission. Using synthesised evidence on the efficacy of NSP and OST(7), the model 
is used to test whether observed decreases in HCV incidence and prevalence amongst PWID from 
2008–2015 are consistent with the scale-up of interventions over this period, and then quantify the 
impact of the national HCV and drug strategies that resulted in this scale-up. This dynamic 
transmission process is something that could not be tested with a statistical model.   
 
Methods 
 
Model description  
A dynamic, deterministic mathematical model of HCV transmission amongst PWID was developed. 
The PWID population was stratified into current (had injected in the previous year) and temporarily 
ceased (had not injected in the previous year) PWID. These groups were divided into short-term (<1 
year since onset), mid-term (1–9 years since onset) and long-term (≥10 years since onset) PWID, 
  
stratified into those on OST and high coverage NSP, as well as whether they were high-risk (defined 
as either currently homeless or injecting stimulants) or not (Supplementary Figure S1a).   
 
PWID enter the model through initiating injecting into the current, short-term injecting group, and 
leave through permanently ceasing injecting (from the temporarily ceased groups) or through drug-
related or non-drug related mortality (all groups). All PWID enter the model with no coverage of OST 
or high coverage NSP, with a time-varying proportion being high- or low-risk (see Model 
Parameterisation). PWID transition between different injecting, intervention and risk states at 
specified rates. All transitions are bi-directional except for those between injecting durations. All 
current PWID can temporarily cease injecting (more likely if on OST), with these PWID then either 
leaving the model due to permanently ceasing injecting or returning to currently injecting status.  
 
The model is also stratified by HCV infection status (Supplementary Figure S1b), with all new PWID 
being susceptible to infection. The model simulates transmission of HCV amongst currently injecting 
PWID, with transmission occurring at a per-capita rate dependent on the injecting risk (high-risk or 
not), intervention status (OST and/or high coverage NSP), and duration of injecting (Supplementary 
Materials for further details). Once infected, PWID either transition to the chronically infected group, 
or spontaneously clear infection, transitioning to the previously infected group. Due to uncertainty 
in the evidence(25-29), we assume that previously infected PWID are re-infected with the same risk 
as for primary infections of susceptible PWID. Chronically infected individuals can be treated, 
whereupon they either attain a sustained viral response (SVR) and move to the previously infected 
group, or transition to the treatment failure group.  In the baseline model, treatment failures are not 
retreated.  The model assumes that PWID mix to form transmission contacts, with a user defined 
proportion of these contacts being formed randomly proportional to the overall transmission risk of 
PWID in different sub-groups, and the remainder being formed assortatively (like-with-like) with 
PWID of the same duration of injecting (short-term, mid-term or long-term) or risk level (high- or 
low-risk).  
 
 
Model parameterisation 
The model was primarily parameterised and calibrated using data from four large surveys (n=2194-
3315 for each survey) undertaken amongst people who had ever injected drugs (~80% had injected 
in the previous 6 months), recruited from ~100 (50% of all) sites providing injecting equipment 
across Scotland between 2008-2014: the Needle Exchange Surveillance Initiative (NESI) 
surveys(5,6,30). Data analyses were undertaken using Stata Version 14.2. Historical survey data, 
intervention output, and PWID size estimation data were also incorporated as described below, with 
the data sources described in the Supplementary Materials.  
 
Risk-status parameters 
Risk Status: Post-2005, data from the NESI surveys and two other cross-sectional surveys conducted 
in Glasgow (2005 and 2007)(31) were used to estimate the proportion of PWID that were high-risk 
(defined by either being homeless in the past six months or currently injecting stimulants – both 
associated with increased HCV risk in the NESI datasets) for different durations of injecting. The 
prevalence of high-risk behaviours was greater in those with shorter rather than longer injecting 
durations, and so this was incorporated into the model.  
 
Intervention parameters 
OST Coverage: We assumed OST started in 1985, in response to the spread of HIV infection among 
PWID. Estimates of OST coverage amongst PWID in Scotland between 1995-2014 were derived from 
data on methadone prescriptions dispensed across Scotland(32-34), and self-reported survey data 
  
on OST uptake from Glasgow (2005)(31) and the NESI surveys. NESI data suggested higher OST 
coverage amongst those injecting for longer, which was incorporated into the model (Table S2).  
 
NSP Coverage: NSP coverage was estimated from the number of syringes distributed in Glasgow or 
nationally from 1988/89 to 2012/13(5,35-37), estimates of the number of PWID in Scotland(38), and 
the average injecting frequency while accounting for differences by OST status (from NESI) and the 
changing coverage of OST. Due to high NSP coverage across all injecting durations, we assumed the 
same coverage for all PWID.  
 
HCV Risk: Data from a UK pooled analysis were used to parameterise the degree to which being on 
OST, high coverage NSP, or both reduces the risk of acquiring HCV(7,39). Using NESI, risk ratios were 
calculated for the increased risk of HCV acquisition associated with being homeless or injecting 
stimulants (denoted as high-risk), and for different durations of injection. These increases in risk 
status were not found to differ if adjusted for OST and high coverage NSP status.  
 
HCV Treatment: Pre-2002, PWID were not recommended for HCV treatment in the UK(40). Post-
2002, data on the number of treatments in Scotland were used to estimate the number occurring 
amongst PWID(41). We calculated a weighted SVR rate and treatment duration based on the 
genotype distribution(42-44), and assumed that only PWID on OST are treated based on current HCV 
treatment/care pathways in Scotland(45).  
 
PWID related parameters 
Injecting Duration: Data on injecting cessation (1/duration) and relapse were based on the 
Edinburgh Addiction cohort(46,47).  
 
Probability distributions were attached to all uncertain model parameters and calibration data 
thought to affect the decrease in HCV prevalence and incidence. Parameter values and distributions 
used in the model are shown in Table 1, while calibration data from NESI are given in supplementary 
Table S2. More details on the model parameterisation is included in the Supplementary Materials. 
 
[Table 1 here] 
 
Model calibration 
A Bayesian model-fitting algorithm was used for model calibration. Five-thousand model parameter 
sets were randomly sampled from the parameter uncertainty distributions in Table 1, and 5,000 HCV 
sero-prevalence estimates for current PWID in 2008/09.  
 
Other parameters were not sampled, but estimated for each parameter set. Through fitting reduced 
sub-models to specific data quantities, estimates were generated for the: (1) rate PWID initiate 
injecting by fitting to the sampled PWID population size; (2 and 3) time varying recruitment rates 
onto OST and NSP by fitting to the sampled OST and high coverage NSP coverage for specified years 
(1985, 2005, 2008 and 2013/14 for OST; and 1990, 2008 and 2011/12 for NSP); and (4) proportion 
high-risk when initiating injecting and transition rates from low to high-risk by fitting to the sampled 
proportion high-risk for specified years (1990, 2005, 2008 and 2013/14). See Supplementary 
Materials for more detail.  
 
These fitted parameters, along with the initially sampled parameters, were used to calibrate the full 
model to the sampled HCV sero-prevalence amongst current PWID for 2008/09 by varying the 
overall transmission rate amongst PWID. These preliminary model fits to the overall HCV sero-
prevalence in 2008/09 were compared against the HCV sero-prevalence amongst short-term PWID 
and incidence in current PWID, both from NESI in 2008/09. Any run that lay within the 95% 
  
confidence bounds for both quantities was accepted as a baseline model fit. From 5,000 sampled 
parameter sets, 581 baseline model fits were obtained, which were used for all subsequent 
analyses. It is noteworthy that the baseline model fits were not calibrated to any HCV 
epidemiological data from later surveys, or mid-term or long-term PWID. All model fitting used the 
lsqnonlin algorithm in MATLAB 2016a.  
 
Model analyses 
Projections from all baseline model fits were compared against all available NESI HCV incidence 
estimates (2008/09, 2010, 2011/12 and 2013/14) for short-term, mid-term and long-term PWID – in 
total 12 data points. This was done to assess whether the model replicated the observed decreases 
in these epidemiological measures while incorporating the observed scale-up of interventions and 
decrease in high-risk status over time. Specifically, we estimated the percentage of the 95% 
confidence intervals for these 12 data points that each baseline model fit lay within, and estimated 
the average of this across all baseline model fits. 
 
We also generated model projections using all baseline model fits for a full counterfactual of no 
increase in intervention coverage (OST, NSP and HCV treatment) or decrease in high-risk behaviour 
post-2008, and partial counterfactuals assuming one or more of the intervention components were 
at constant coverage post-2008. The full and partial counterfactuals were used to estimate the 
number of HCV infections averted due to each intervention component, and the relative change in 
HCV incidence that would have occurred without any changes in intervention coverage or high-risk 
behaviour post-2008. 95% credibility intervals (95%CrI) were produced using the 2.5 to 97.5 
percentile range in the projections across the model fits. 
 
Lastly, an analysis of co-variance (ANCOVA) was performed on the relative decrease in incidence 
between 2008-2015 when all interventions were scaled up, and on the number of HCV infections 
averted over this period compared to the full counterfactual. This determined the importance of 
uncertainty in different parameters to the variability in these outcomes by calculating the proportion 
of the sum of squares contributed by each parameter(48).  
 
Results 
Model comparison with available data  
The baseline ‘intervention’ model accurately captures the overall (Figure 1, and by injecting 
duration–Figure S3) increasing trend in OST and NSP coverage, and decreasing trend in ‘high-risk’ 
PWID between 2008/09-2013/14. Although not calibrated to HCV incidence data post-2008/09, 
Figures 2 and S4 show the model reproduces observed trends in HCV incidence from NESI between 
2008–2014, overall and by different injecting duration categories. Indeed, on average, each baseline 
model fit lies within 84% (10.1/12) of the confidence bounds (95% confidence intervals) for the 12 
incidence data points that the model was compared against – none of which were fit to. The model 
also, though to a lesser extent, reproduces the trends in HCV prevalence (Figure 2 and Figure S4).  
 
[Figure 1 and 2 here] 
 
Impact of intervention 
The model projects a mean baseline incidence of 14.2 per 100pyrs (95%CrI 9.0-20.7) amongst 
current PWID in 2008. When incorporating all changes in intervention coverage and high-risk status, 
the baseline ‘intervention’ model projects that between 2008–2015, HCV incidence amongst current 
PWID decreased by 61.3% (95%CrI 45.1-75.3%) to 5.5 per 100pyrs (95%CrI 2.9-9.2) (Table 2). 
However, the counterfactual model suggests without this intervention scale-up or change in high-
risk status since 2008, HCV incidence could still have decreased (Table 2 and Figures 3/S4) by a 
  
quarter (27.4%, 95%CrI 17.6-37.0%) to 10.3 per 100pyrs (95%CrI 6.1-15.7) by 2015. Therefore, we 
estimate that increases in intervention coverage and decreases in high-risk status post-2008 resulted 
in an additional 33.9% decrease (95%CrI 23.8-44.6%) in HCV incidence. This translates to 1,492 
(95%CrI 657-2,646) HCV infections averted between 2008–2015 or 31.3% (95%CrI 16.1-50.7%) of all 
HCV infections (Table 2) occurring over that period compared to the counterfactual model. Most of 
the HCV infections averted (66.8%, 95%CrI 39.9-83.7%) were due to scale-up in OST and NSP post-
2008, which averted 1,016 (95%CrI 308-1,996) HCV infections, whereas HCV treatment averted 72 
(95%CrI 27-137) infections (Table 2) with the remainder (404, 95%CrI 150-836) due to decreases in 
high-risk PWID.  
 
[Table 2 and figure 3 here] 
 
ANCOVA analysis 
ANCOVA analysis indicates that the largest contributor to the variability in the impact projections for 
HCV incidence came from uncertainty in the efficacy of being on both OST and NSP for reducing HCV 
acquisition risk (36% of the variation), and uncertainty in the efficacy of NSP alone (31% of variation). 
Uncertainty in the increased risk of transmission amongst short-term and mid-term PWID 
contributed 7% and 3% of the variation, respectively, whereas all other parameters contributed less 
than 3% (Supplementary Figure S5). 
 
Variability in the number of infections averted was mainly due to uncertainty in the turnover and 
size of the PWID population. Approximately 30% of the variation was due to uncertainty in the 
temporary cessation rate amongst mid-term and long-term PWID, whilst uncertainty in the 
permanent cessation rate, injecting relapse rate and PWID population size contributed a further 
16%, 10% and 10% to the variation, respectively (Supplementary Figure S5).  
 
Discussion 
Our model projections suggest that historical changes in intervention coverage and injecting risk pre- 
2008 would themselves have resulted in HCV incidence decreasing among PWID in Scotland, from 
approximately 14 per 100pyrs in 2008 to 10 per 100pyrs in 2015.  Additionally, scaling-up opioid 
substitution therapy (OST) and needle and syringe provision (NSP) post-2008 contributed a further 
reduction in HCV incidence to 5 per 100pyrs by 2015, and an estimated 1,400 HCV infections averted 
over 7-years. HCV treatment scale-up, however, has only had modest impact to date, averting an 
estimated 72 infections by 2015. This small impact of HCV treatment is both due to few (<5%) 
infected PWID being treated per year between 2008-2015, and HCV treatment only averting 
infections indirectly, first through reducing prevalence and as a by-product reducing the risk that 
someone becomes infected from an infected PWID. 
  
Strengths and limitations 
The strengths of our modelling are that it was developed and parameterised using detailed data on 
the local epidemic and intervention coverage in Scotland, and was validated through its ability to 
mimic the changing epidemic patterns amongst PWID in Scotland between 2008-2015, despite only 
being fitted to epidemiological data for 2008/09. However, limitations still exist.   
First, the model did not simulate precisely all epidemiological trends from the NESI surveys.  Model 
projections of HCV antibody-prevalence post-2008 tended to be lower than observed trends in 
Scotland. This may be due to more injectors continuing to inject than the model projected, thereby 
not fully capturing the long-term dynamics of injecting. Alternatively, the NESI survey may not be 
representative of all PWID, possibly through over sampling older PWID. Both factors could reduce 
the resulting observed impact of decreases in HCV incidence on reducing HCV prevalence overall, 
  
which is largely a product of population turnover. However, this would not affect the impact of 
intervention scale-up on more recently initiated PWID (which were simulated more accurately) 
where most new HCV infections occur.  
Second, the counterfactual model also projected a decrease in HCV incidence. Figure S4 shows that 
it agrees equally well with observed trends in HCV incidence as the intervention model, mainly due 
to the upturn in HCV incidence between 2011/12-2013/14 (NESI). This emphasises that without 
strong evidence for intervention scale-up over this period, it would have been impossible to decide 
whether the observed decreases in HCV incidence were due to improvements in intervention 
coverage or other historical changes.  
Third, several model parameters were uncertain – including intervention effect estimates for OST 
and NSP, historical OST and NSP coverage, dynamics of high-risk behaviours, cessation and relapse 
rates, and the PWID prevalence in Scotland over time. Our projections incorporated uncertainty in 
all these parameters, and although they were robust despite this it did result in a low hit rate during 
the model calibration (581 of 5,000 model runs were a baseline model fit). Importantly, most 
imprecision resulted from uncertainty in the efficacy of NSP (alongside OST or not) and factors 
related to PWID population turnover and size, highlighting the need for better data on these 
quantities.  
Finally, we assume that the decrease in high-risk behaviours in PWID is independent of the scale-up 
in harm reduction measures and treatment. Whilst evidence from Scotland and a recent Cochrane 
review shows that OST decreases the risk of HCV acquisition through reducing the frequency of 
injecting, independent of this, homelessness and stimulant injecting still increase the risk of HCV 
transmission in Scotland, as shown in a recent pooled analysis(49). It is possible that the increase in 
OST and or NSP coverage may have decreased the prevalence of high-risk behaviours, but due to a 
lack of data to support this it was not included as a model assumption.  
Comparison with other studies 
Previous modelling studies have estimated the impact of OST, NSP (8,11-13) and HCV 
treatment(14,15,50,51) on HCV transmission at the population-level, but none have validated 
whether their projections are consistent with observed epidemiological data. In contrast, our model 
projections evaluate the evidence that increases in intervention coverage impacted on observed 
population-level HCV incidence trends. Evidence from Scotland shows that these interventions are 
associated with decreases in HCV acquisition risk at the individual-level, and that HCV incidence 
decreased at the population-level concurrently with their scale-up(5).  However, these 
epidemiological analyses did not determine whether the observed decrease in incidence was 
consistent with the scale-up in intervention coverage; nor did they account for possible decreases in 
HCV transmission due to historical changes in intervention coverage and evolving epidemic 
dynamics. These are issues that modelling can address, as done in this analysis. Only one previous 
analysis has considered a similar question for HCV; modelling from Amsterdam showed that 
historical changes in risk behaviour prior to intervention scale-up contributed most to observed 
reductions in HCV incidence in Amsterdam(11).  
Implications and Conclusions 
Our model projections provide good evidence that the observed decline in HCV incidence in Scotland 
post-2008 was largely due to increased OST and NSP coverage, made possible through strategies 
implemented by the Scottish Government. These strategies provided dedicated funding for 
prevention(52), and set targets for improvements in services relating to injection equipment 
provision, HCV treatment, and treatment for addiction.  
Our model projections also highlight uncertainty in the evidence base. Further data collection is 
needed to better evaluate the role of NSP in decreasing HCV transmission risk, preferably from 
  
multiple studies using comparable measures of coverage or intervention intensity(7,39). 
Additionally, more linkage studies are needed to better capture the natural history and transitions 
between injecting risk states for PWID populations(46,53,54). Both these factors contributed 
considerable uncertainty to our projections.    
This study illustrates how a country-level HCV action plan incorporating scale-up of a range of HCV 
prevention interventions can markedly reduce HCV incidence. This contrasts sharply with most 
countries where restrictions in these interventions, due to funding limitations or legal 
constraints(55), severely limit their impact on HCV incidence(56-61). However, even with high OST 
and NSP coverage, the impact achieved in Scotland still falls short of the World Health Organisation’s 
strategy for reducing HCV incidence by 90%(62), highlighting that additional interventions are 
required to eliminate HCV. This could include scaling-up HCV treatment, which modelling has 
suggested could have substantial impact(12,50), and the scale-up of other interventions to reduce 
HCV transmission, such as: safe injecting facilities(63); expanding the use of low dead space 
syringes(64,65); or interventions such as prison-based OST to reduce the heightened risk associated 
with incarceration(66,67). This model could be an invaluable tool for determining which of these 
interventions are now needed to reduce HCV transmission to elimination levels in Scotland. 
 
 
  
Tables 
Table 1: Model parameters with 95% confidence intervals in brackets. Ranges and sampling distributions for parameters varied in the model fitting are 
shown in bold.   
Parameter Symbol Value Reference Sampled range Distribution 
      
Risk status parameters:      
Duration stay high-risk in years 1/𝜎 1.2 (68)   
Relative risk (compared to low-risk) for acquiring HCV if high-risk for different durations of injecting   
for short-term high-risk PWID  𝜓0 4.7 (1.7 – 17.5) Calculated using NESI (30) 4.7 (1.7 – 17.5) Log normal 
mid-term high-risk PWID 𝜓1 3.0 (1.5 – 6.1) 3.0 (1.5 – 6.1) Log normal 
      
Intervention parameters: 
OST and high coverage NSP      
Duration on OST in years 1/𝛾 2/3 (69)   
Duration on high coverage NSP in years 1/𝜅 2/3 Assume same as OST   
Relative risk (compared to no intervention state) for acquiring HCV for different intervention 
states 
   
while on OST and not on high coverage NSP Γ 0.48 (0.17 – 1.33) (7) 0.48 (0.17 – 1.33) Log normal 
while on high coverage NSP and not on OST Π 0.5 (0.22 – 1.12) (7) 0.5 (0.22 – 1.12) Log normal 
while on OST and high coverage NSP Β 0.21 (0.08 – 0.52) (7) 0.21 (0.08 – 0.52) Log normal 
Treatment parameters:       
Annual treatment rate from 2009 to 2015 amongst     
Currently injecting PWID  Φ0 150 per year (75 – 225)
b HCV register/link (41,43) 150 (75 – 225) Normal 
Temporarily ceased PWID Φ1 300 per year (150–450)
b 300 (150 – 450) Normal 
Percentage of infections genotype 1 (G1)  47.8% (46.9 – 48.6%) (42) 47.8% (46.9 – 48.6%) Normal 
SVR: PEG-INF-RBV (G1) 
𝜶a 
39.0% (33.6 – 44.7%) (70) 39.0% (33.6 – 44.7%) Normal 
SVR: PEG-INF-RBV (G2/3) 69.7% (65.8 – 73.4%) (70) 69.7% (65.8 – 73.4%) Normal 
Average treatment duration (G1 SVR) 1/𝜔a 
 
48/52 years (44)   
Average treatment duration (G1 no SVR) 12/52 years   
Average treatment duration (G2/3) 24/52 years   
      
PWID-related parameters 
Current PWID population size Vary 𝜃 to fit 16000 (11500 – 19400) (38) 16000 (12050 – 19950)c Normal 
PWID mortality rate per year 𝜇 1% (71) 0.01 Poisson 
Proportion temporarily ceased amongst 
short-term PWID 
𝑝0 0.46 (0.41 – 0.50) (46) 0.23 – 0.69
d Uniform 
  
Increased temporary cessation rate if on OST 𝜏 1.71 (1.40 – 2.09) (46) 1.36 – 2.07d Uniform 
Probability of relapsing within 1 year Used to find 
relapse and 
permanent 
cessation 
rates (𝑞1, 𝑞1) 
0.37 (0.32 – 0.42) (46) 0.185 – 0.555d Uniform 
Probability of relapsing after 5 years 0.59 (0.54 – 0.64) (46) 0.295 – 0.885d Uniform 
Probability of sustaining cessation at 30 years 
from first cessation 
~0.25 Estimated from Kaplan-
Meier curve (46) 
0.125 – 0.375d Uniform 
Probability of temporary cessation of 
injecting at 5yrs among current injectors. 
Used to find 
temporary 
cessation 
rate (𝑝1) of 
current 
injectors 
0.72 (0.67 – 0.76) (46) 0.36 – 1d Uniform 
Probability of assortative (like-with-like) mixing     
High with low-risk PWID 𝜌 0 – 0.5 Little data (from Bristol) 
suggests probability 
should be 0.3 or less – 
wide range used because 
data is uncertain (72) 
0 – 0.5 Uniform 
Between short-term, mid-term and long-term 
PWID  
𝑞 0 – 0.5 0 – 0.5 Uniform  
Proportion spontaneously clear infection 𝛿 0.26 (73)   
 
aAs SVR varies by genotype, the average SVR was calculated using a weighted estimate based on population genotype distribution and SVR. bFor treatment 
numbers, we used uncertainty range of +/- 50%. cWe averaged the distance from mean so we could use a normal distribution for uncertainty range. 
dDoubled range of confidence interval due to uncertainty in this data. Abbreviations: PWID people who inject drugs; OST opioid substitution therapy; HCNSP 
high coverage needle and syringe programmes; G1 genotype 1; G2/3 genotypes 2 or 3; SVR sustained viral response; PEG-INF-RBV pegylated interferon and 
ribavirin.
  
Table 2: Infections averted amongst people who inject drugs and the relative decrease in incidence 
between 2008 and 2015 for the different scenarios of interventions being scaled-up from 2008. 
Ranges in brackets are 95% credibility intervals. 
Change from 2008 to 2015 compared to 
counterfactual 
Mean number 
of infections 
Mean infections 
averted (95% CrI) 
Mean relative 
decrease in incidence  
No change (i.e. no intervention scale-up or 
decrease in proportion high-risk)  
6353  
(3450-9728) 
N/A 27.4% (17.6-37.0%) 
Scale-up of OST and high coverage NSP 
only 
5337  
(3035-8329) 
1016 (308-1996) 47.3% (30.0-62.7%) 
Scale-up of OST and high coverage NSP plus 
decrease in high-risk status 
4933  
(2714-7767) 
1420 (613-2544) 57.9% (41.1-72.3%) 
Scale-up of OST and high coverage NSP plus 
decrease in high risk status plus increase in 
HCV treatment 
4861  
(2646-7681) 
1492 (657-2646) 61.3% (45.1-75.3%) 
Projections are means of model fits, with 95% credibility intervals in brackets 
 
 
  
  
Figures 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
Figure 1: Comparison of model projections with data on the scale-up of (a) OST coverage; (b) NSP 
coverage; (c) percentage of PWID that are high-risk; and (d) number of HCV treatments over time. In 
all graphs, black solid and dashed lines indicate the median projections for the 581 baseline 
‘intervention’ and counterfactual model runs, respectively, whereas light grey triangles indicate the 
mean (whiskers are 95% confidence intervals) estimates for the pre-NESI data and dark grey circles 
indicate the mean (whiskers are 95% confidence intervals) estimates from different rounds of NESI 
or estimates from the period covered by NESI. Note that for NSP coverage, the upper intervals are 
bounded by the mean self-reported NSP coverage from NESI. 
 
  
  
(a) 
 
(b) 
 
(c) 
 
(d) 
 
Figure 2: Model and NESI estimated HCV incidence (figures (a) and (b)) and anti-HCV prevalence 
(figures (c) and (d)) amongst PWID.  (a) HCV incidence amongst all current injectors (b) HCV 
incidence amongst short-term current injectors (injecting <1yrs), (c) Anti-HCV prevalence amongst all 
current injectors, and (d) Anti-HCV prevalence amongst short-term current injectors (injecting <1 
yrs). In all graphs, black solid lines indicate the median projections for the 581 baseline ‘intervention’ 
model runs. The light grey triangles indicate the mean (whiskers are 95% CI) data estimates from 
NESI which were fit too and the dark grey circles indicate the mean (whiskers are 95% CI) data 
estimates from NESI that were not fit to. Note: Anti-HCV prevalence was fit to a wider range of 49-
57%.  
  
  
 
Figure 3: A comparison of NESI HCV incidence estimates for different years (grey and black points) 
with the model projected HCV incidence amongst all PWID (median across all full model fits) for 
different intervention scenarios: no intervention scale-up or decrease in high-risk behaviour from 
2008 onwards (light grey line – full counterfactual); Scale up of OST and high coverage NSP only from 
2008 onwards (dark grey line); Scale up of OST and high coverage NSP plus decrease in high risk 
behaviour from 2008 onwards (single dashed line); Scale up of all interventions from 2008 onwards 
(dash and dotted line – baseline intervention runs). Whiskers denote the 95% CI for each NESI HCV 
incidence estimate.  
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